These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31611911)

  • 1. A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide.
    Chai RC; Chang YZ; Wang QW; Zhang KN; Li JJ; Huang H; Wu F; Liu YQ; Wang YZ
    Front Genet; 2019; 10():910. PubMed ID: 31611911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
    Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
    Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide DNA methylation analysis identifies potent CpG signature for temzolomide response in non-G-CIMP glioblastomas with unmethylated MGMT promoter: MGMT-dependent roles of GPR81.
    Liang BB; Wang YH; Huang JJ; Lin S; Mao GC; Zhou ZJ; Yan WJ; Shan CY; Wu HZ; Etcheverry A; He YL; Liu FF; Kang HF; Yin AA; Zhang SQ
    CNS Neurosci Ther; 2024 Apr; 30(4):e14465. PubMed ID: 37830163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
    Wang J; Zhang M; Liu YF; Yao Y; Ji YS; Etcheverry A; Chen K; Song BQ; Lin W; Yin A; He YL
    Epigenomics; 2022 Oct; 14(20):1233-1247. PubMed ID: 36444681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.
    Jiang S; Rui Q; Wang Y; Heo HY; Zou T; Yu H; Zhang Y; Wang X; Du Y; Wen X; Chen F; Wang J; Eberhart CG; Zhou J; Wen Z
    Eur Radiol; 2018 May; 28(5):2115-2123. PubMed ID: 29234914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas.
    Li B; Wang J; Liu F; Li R; Hu W; Etcheverry A; Aubry M; Mosser J; Yin A; Zhang X; Wu Y; Chen K; He Y; Wang L
    J Oncol; 2022; 2022():6345160. PubMed ID: 35712126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.
    Guo G; Gong K; Puliyappadamba VT; Panchani N; Pan E; Mukherjee B; Damanwalla Z; Bharia S; Hatanpaa KJ; Gerber DE; Mickey BE; Patel TR; Sarkaria JN; Zhao D; Burma S; Habib AA
    Neuro Oncol; 2019 Dec; 21(12):1529-1539. PubMed ID: 31363754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis.
    Alnahhas I; Alsawas M; Rayi A; Palmer JD; Raval R; Ong S; Giglio P; Murad MH; Puduvalli V
    Neurooncol Adv; 2020; 2(1):vdaa082. PubMed ID: 33150334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. O
    Bobola MS; Alnoor M; Chen JY; Kolstoe DD; Silbergeld DL; Rostomily RC; Blank A; Chamberlain MC; Silber JR
    BBA Clin; 2015 Jun; 3():1-10. PubMed ID: 25558448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
    Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
    J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of
    Zappe K; Pühringer K; Pflug S; Berger D; Weis S; Spiegl-Kreinecker S; Cichna-Markl M
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation.
    McDonald KL; Tabone T; Nowak AK; Erber WN
    Oncol Lett; 2015 May; 9(5):2063-2067. PubMed ID: 26137013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of
    Lam K; Eldred BSC; Kevan B; Pianka S; Eldred BA; Zapanta Rinonos S; Yong WH; Liau LM; Nghiemphu PL; Cloughesy TF; Green RM; Lai A
    Neurooncol Adv; 2022; 4(1):vdac030. PubMed ID: 35386566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
    Grossman R; Burger P; Soudry E; Tyler B; Chaichana KL; Weingart J; Olivi A; Gallia GL; Sidransky D; Quiñones-Hinojosa A; Ye X; Brem H
    J Clin Neurosci; 2015 Dec; 22(12):1938-42. PubMed ID: 26249244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication.
    Wei J; Yang G; Hao X; Gu D; Tan Y; Wang X; Dong D; Zhang S; Wang L; Zhang H; Tian J
    Eur Radiol; 2019 Feb; 29(2):877-888. PubMed ID: 30039219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
    Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
    J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of Glioblastomas.
    Cai HQ; Liu AS; Zhang MJ; Liu HJ; Meng XL; Qian HP; Wan JH
    Front Oncol; 2020; 10():669. PubMed ID: 32528873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.